Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, OSAKA, and IWATE, September 2nd, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ), Nitto Denko Corporation (TSE: 6988, President; Hideo Takasaki, “Nitto”), and M. Heart Co., Ltd. (President and CEO: Yoshimi...
Read more about Astellas, Nitto, and M. Heart Partnering for ECG testing service
TOKYO, September 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients...
TOKYO, August 31, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D.) today announced that the personnel changes as below...
TOKYO, August 20, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZOTM...
TOKYO, August 6, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will change its research organization as of October 1, 2021 as follows...
TOKYO, Japan, and Haifa, Israel, July 30, 2021 - Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced a worldwide strategic collaboration...
TOKYO and Iwate, July 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and M. Heart Co., Ltd. (Headquarters: Iwate, President and CEO: Yoshimi Mizunuma, "M. Heart") launched "MYHOLTER II", a software for the holter...
Read more about Begun Providing Holter ECG Analysis Service using AI
CAMBRIDGE, Mass, USA, and TOKYO, Japan, July 13, 2021 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae...
TOKYO, July 13, 2021 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for 10 consecutive years, as a company that is performing excellent initiatives in the areas of ESG...
Read more about Astellas Named to FTSE4Good Index Series for 10 Consecutive Years
TOKYO and BOTHELL, Wash.– July 9, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted PADCEV® (enfortumab vedotin-ejfv)...
Follow us
